GRIN2A

Glutamate receptor ionotropic, NMDA 2A · Q12879 · GRIN2A on Sugi Atlas →

144,000 patent compounds predicted against GRIN2A, 86,704 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Ditolylguanidine (SCHEMBL80339)	1.00	14/20
SCHEMBL103515	0.67	13/20
SCHEMBL27318	0.54	12/20
Guanabenz (SCHEMBL15390)	0.65	11/20
Memantine (SCHEMBL2688)	1.00	10/20
Memantine (SCHEMBL2689)	1.00	10/20
Memantine (SCHEMBL3053)	1.00	10/20
Levorphanol (SCHEMBL24335)	1.00	9/20
Racemorphan (SCHEMBL46201)	1.00	9/20
Dextrorphan (SCHEMBL115577)	1.00	9/20
SCHEMBL106036	0.45	9/20
SCHEMBL72366	0.43	9/20
Dextromethorphan (SCHEMBL29949)	1.00	8/20
Levomethorphan (SCHEMBL29950)	1.00	8/20
Tacrine (SCHEMBL3270)	0.97	8/20
SCHEMBL103596	0.44	8/20
SCHEMBL78658	1.00	7/20
Radiprodil (SCHEMBL99256)	1.00	7/20
SCHEMBL105665	0.43	7/20
Amantadine (SCHEMBL4098)	1.00	6/20

Clinical trials — most relevant to GRIN2A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
PCA Ketamine-Morphine VS PCA Morphine as Post-Operative Analgesia in Colorectal Surgery.	PHASE4	COMPLETED
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine	PHASE4	COMPLETED
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders	PHASE3	RECRUITING
Memantine for Refractory OCD Patients	PHASE3	UNKNOWN
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial	PHASE2/PHASE3	NOT_YET_RECRUITING
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)	PHASE2/PHASE3	RECRUITING
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease	PHASE3	COMPLETED
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder	PHASE2	COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia	PHASE2	UNKNOWN
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
NMDA Modulation in Major Depressive Disorder	PHASE2	RECRUITING
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression	PHASE1	RECRUITING
Brain Imaging, Genetics and Treatment for Major Depression	PHASE1	WITHDRAWN
Antidepressant Effects of NR2B in Major Depression	PHASE1	COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial	PHASE1	COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response	PHASE1	RECRUITING
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia	PHASE1	COMPLETED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy	nan	UNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
An Assessment of Cognitive Function in Irritable Bowel Syndrome	nan	UNKNOWN
Acamprosate: Genes Associated With Response	nan	COMPLETED
Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus	nan	COMPLETED
Mechanisms of Human Plasticity in the Human System	nan	COMPLETED
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients	nan	COMPLETED
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX	nan	COMPLETED
In Vitro Modeling of Drug-resistant Psychiatric Disorders Using Induced Pluripotent Cells	nan	UNKNOWN
7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a GRIN2A binder may also engage these)

Protein	Name	Similarity
P35436	—	1.000	P35436 →
Q5IS45	—	1.000	Q5IS45 →
B7ZSK1	—	1.000	B7ZSK1 →
Q00959	—	1.000	Q00959 →
A7XY94	—	0.999	A7XY94 →
GRIN2B	Glutamate receptor ionotropic, NMDA 2B	0.993	landscape →
Q5R1P3	—	0.993	Q5R1P3 →
Q00960	—	0.992	Q00960 →
Q01097	—	0.991	Q01097 →
B4MU83	—	0.988	B4MU83 →
B3LZ39	—	0.986	B3LZ39 →
B4JHV0	—	0.986	B4JHV0 →
Q24418	—	0.985	Q24418 →
B4LZB5	—	0.985	B4LZB5 →
B4PVB0	—	0.984	B4PVB0 →
B4KD90	—	0.984	B4KD90 →
B4I414	—	0.983	B4I414 →
B4QWW7	—	0.983	B4QWW7 →
B4GF83	—	0.982	B4GF83 →
Q296F7	—	0.982	Q296F7 →
B3P2E5	—	0.981	B3P2E5 →
A0A1S4F362	—	0.975	A0A1S4F362 →
P19492	—	0.974	P19492 →
Q9Z2W8	—	0.974	Q9Z2W8 →
GRIA3	Glutamate receptor 3	0.973	landscape →
Q9Z2W9	—	0.973	Q9Z2W9 →
GRIA2	Glutamate receptor 2	0.972	landscape →
GRIA4	Glutamate receptor 4	0.971	landscape →
Q38PU6	—	0.970	Q38PU6 →
Q9W365	—	0.970	Q9W365 →